Bylaws
for the Nordic Study Group on Myeloproliferative neoplasms (NMPN)
§ 1. The aim and purpose of NMPN is to promote better treatment for patients
with the myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia
and idiopathic myelofibrosis. This is to be achieved through the performance of
phase I-II studies of new treatment modalities and randomized phase III-IV trials
in collaboration with other European working groups. Another important part of
NMPN:s work is preclinical in vitro studies of different aspects of the myeloproliferative
disorders. Finally, evidence based clinical care programmes will be updated on
a regular basis. The activities of the NMPN are performed by different subgroups
that are formed for each project.
§ 2. NMPN holds major meetings every 6 months. These meetings are open to
any clinician or scientist with an interest in the myeloproliferative neoplasms.
Between meetings the chairman and the scientific secretary are responsible for
the follow-up of decisions taken at meetings.
§ 3. NMPN is led by a chairman and a scientific secretary. These are elected
by the group with a mandate of three years. The same person(s) can be re-elected
if the group so decides. An election group with one member from each country has
the responsibility to suggest candidates.
§ 4. NMPN has members from Denmark, Finland, Iceland, Norway and Sweden.
§ 5. The activities of NMPN are currently financed by unrestricted research
grants from pharmaceutical companies, Applications for research grants from different
other sources will be submitted on a regular basis. NMPN:s financial account is
currently located at Uppsala University/Academic Hospital. The chairman is responsible
for the account.
§ 6. New protocols, suggestions concerning the election of chairman and/or
secretary, changes in guidelines or bylaws should be distributed to the members
of NMPN at least one month before the next major meeting of the group.
